Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

NCT04266301 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

530

Enrollment

INDUSTRY

Sponsor class

Stopped In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.

Conditions

Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions

DRUG: Sabatolimab
DRUG: Azacitidine
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals